Press monitoring
Histide Announces Publication in Nature Materials Revealing Mechanisms Governing Stem Cell Differentiation
2.12.2015 | Press monitoring
Differentiation of human mesenchymal stem cells can be readily switched from adipogenesis to osteogenesis by modulating expression of microtubule-associated protein DCAMKL1.
Growing stem cells faster on seaweed
2.12.2015 | Press monitoring
Alginate forms a kind of supporting skeleton in the cell walls of certain kinds of algae. Fraunhofer scientists use the gel-like mass from Chilean seaweed as the substrate for stem cells. They can flexibly adjust the pore size and elasticity of the alginate, and it transports active ingredients and has better optical characteristics than plastic...
Novel qPCR-based PrenaTest® Successfully Validated in Clinical Study
2.12.2015 | Press monitoring
Konstanz, Germany, December 1, 2015 / B3C newswire / -- LifeCodexx AG reported today the successful validation of its innovative qPCR-based NIPT assay designed to determine fetal trisomy 21 from maternal blood. The blinded study with close to 700 samples demonstrates clearly that the accuracy of the new qPCR-based PrenaTest® is superior to the...
Sanofi: First Doses of Injectable Polio Vaccine ShanIPV(TM) Soon Available for Indian Infants
30.11.2015 | Press monitoring
Lyon, France - November 30, 2015 - Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first shipment of ShanIPV (TM) , a brand new injectable, inactivated polio vaccine (IPV) manufactured by its affiliate Shantha Biotechnics, in Hyderabad, India, will occur in a couple of days. These first vaccine doses will be available to...
Medtronic Enhances Utility of Professional Continuous Glucose Monitor (CGM) by Launching Pattern Snapshot for iPro®2 Professional CGM
30.11.2015 | Press monitoring
DUBLIN - November 30, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the availability of a new CareLink ® iPro report called Pattern Snapshot for iPro2 Professional CGM system. The new one-page report provides a health care professional (HCP) with information for quick interpretation of detailed glucose...
Biocartis Group NV: Biocartis announces launch of Influenza-Respiratory Virus Panel on the Idylla(TM) platform
30.11.2015 | Press monitoring
Mechelen, Belgium, 30 November 2015 - Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces the launch of its first infectious disease test on the Idylla(TM) platform. The Idylla(TM) Respiratory IFV-RSV Panel has been developed by Janssen Diagnostics and is intended for the detection of various strains...
Climate-friendly rice recognized as a top science development of 2015
30.11.2015 | Press monitoring
The creation of a new kind of rice which gives off nearly zero greenhouse gas emissions during its growth has earned kudos for a team of scientists from three continents, including the lead investigator at the Department of Energy's Pacific Northwest National Laboratory. The new kind of rice grows in a manner that nearly eliminates the...
MPI unblinds prospective study of LungChip prognosticator in early lung cancer
27.11.2015 | Press monitoring
Hoersholm; November 27, 2015 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that the prospective LungChip study has been unblinded. LungChip is a prognostic tool for predicting which patients have a good or a bad prognosis of their lung cancer, which can have impact on treatment.
Mission space food: Sugar-growing bacteria go into orbit
27.11.2015 | Press monitoring
Matt Damon’s character in The Martian has to grow potatoes in his own faeces to survive on Mars. But there may be more appealing ways to make food in space, like using bacteria to make chemicals we can eat, such as sugar. The idea is now set to be put to the test in space for the first time. Genetically modified bacteria will be sent up on a...
ABLYNX announces nanobody drug discovery collaboration with NOVO NORDISK
25.11.2015 | Press monitoring
GHENT, Belgium, 25 November 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has entered into a global exclusive collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody ® drug candidates for use in an undisclosed disease area, with an option to expand the agreement to...
